Sign In
Buy SPRB
$42.83
-0.540 (-1.25%)
At Close: Jul 31, 2026
Does Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect?
10:56am, Wednesday, 18'th Mar 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 208.3% in Spruce Biosciences (SPRB). While the effectiveness of this highly sought-after metric is questionable
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates
07:05am, Monday, 09'th Mar 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer
07:00am, Monday, 09'th Mar 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
Spruce Biosciences Touts MPS IIIB Data, Targets Q4 BLA Submission at Oppenheimer Conference
04:30am, Tuesday, 03'rd Mar 2026
Executives from Spruce Biosciences (NASDAQ: SPRB) outlined regulatory plans, clinical data highlights, and commercial considerations for the company's lead program in Sanfilippo syndrome type B (MPS I
Spruce Biosciences to Present at Upcoming Investor Conferences in March
04:05pm, Monday, 02'nd Mar 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
07:00am, Wednesday, 18'th Feb 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
04:05pm, Tuesday, 17'th Feb 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team
08:00am, Tuesday, 03'rd Feb 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™
08:00am, Wednesday, 28'th Jan 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences
07:24am, Wednesday, 21'st Jan 2026
Hong Kong-based Harbour BioMed on Sunday exercised its warrant to acquire the common stock in Spruce Biosciences Inc. (NASDAQ: SPRB).
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
07:02pm, Sunday, 18'th Jan 2026
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of no
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
08:00am, Thursday, 08'th Jan 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Spruce) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neu
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors
08:00am, Monday, 15'th Dec 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
04:05pm, Monday, 10'th Nov 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological
